Table 2.

Complete response with targeted therapies in randomized phase III trials of advanced hepatocellular carcinoma

			Complete response according to
Study (reference)	Compound (N of patients)	Radiological criteria used	Investigator assessment, N (%)	Central independent review, N (%)
SHARP [32]	Sorafenib (299)	RECIST	N/R	0
	Placebo (303)	RECIST	N/R	0
Asia-Pacific [28]	Sorafenib (150)	RECIST	N/R	0
	Placebo (76)	RECIST	N/R	0
SUN 1170 [29]	Sunitinib (530)	RECIST	2 (<1)	N/R
	Sorafenib (544)	RECIST	1 (<1)	N/R
BRISK-PS [31]	Brivanib (263)	mRECIST	N/R	0
	Placebo (132)	mRECIST	N/R	0
BRISK-FL [30]	Brivanib (577)	mRECIST	2 (<1)	N/R
	Sorafenib (578)	mRECIST	5 (1)	N/R
EVOLVE-1 [33]	Everolimus (362)	RECIST	0	N/R
	Placebo (184)	RECIST	0	N/R
LIGHT [27]	Linifanib (514)	RECIST 1.1	N/R	N/R
	Sorafenib (521)	RECIST 1.1	N/R	N/R
SEARCH [35]	Sorafenib + Erlotinib (362)	RECIST	2 (<1)	N/R
	Sorafenib (358)	RECIST	1 (<1)	N/R
REACH [34]	Ramucirumab (283)	RECIST 1.1	1 (<1)	N/R
	Placebo (282)	RECIST 1.1	0	N/R
RESORCE [36]	Regorafenib (379)	mRECIST/RECIST 1.1	2 (1%)/0	N/R
	Placebo (194)	mRECIST/RECIST 1.1	0/0	N/R
REFLECT [6]	Lenvatinib (478)	mRECIST/RECIST 1.1	6 (1)/−	10 (2)/2 (<1)
	Sorafenib (476)	mRECIST/RECIST 1.1	2 (<1)/−	4 (1)/1 (<1)
METIV-HCC [38]	Tivantinib (226)	RECIST 1.1	N/R	0
	Placebo (114)	RECIST 1.1	N/R	0
JET-HCC [37]	Tivanitinib (134)	RECIST 1.1	N/R	N/R
	Placebo (61)	RECIST 1.1	N/R	N/R
CELESTIAL [8]	Cabozantinib (470)	RECIST 1.1	0	N/R
	Placebo (237)	RECIST 1.1	0	N/R
REACH-2 [7]	Ramucirumab	RECIST 1.1	0	N/R
	Placebo	RECIST 1.1	0	N/R

mRECIST modified Response Evaluation Criteria in Solid Tumors; N/R not reported; RECIST Response Evaluation Criteria in Solid Tumors; RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1